Successful Study With Tracleer(r) in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension
Successful Study With Tracleer(r) in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension
ALLSCHWIL, Switzerland, Dec. 17, 2006 — Actelion Ltd announced today that initial results from the double-blind, placebo-controlled, multicenter study EARLY indicate that six months of treatment with the dual endothelin receptor antagonist bosentan (Tracleer) showed a significant reduction in pulmonary vascular resistance, a strong trend towards improved exercise capacity and a significant …



